Safety and efficacy of denosumab in children with osteogenesis imperfecta - a first prospective trial

OBJECTIVES: Osteogenesis imperfecta (OI) is a rare hereditary disease leading to bone fragility. Denosumab as a RANK ligand antibody inhibiting osteoclast maturation has been approved for osteoporosis treatment in adults. Aim of this study was a 48-week, open-label, pilot study of the safety and eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoyer-Kuhn, H., Franklin, J., Allo, G., Kron, M., Netzer, C., Eysel, P., Hero, B., Schoenau, E., Semler, O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Society of Musculoskeletal and Neuronal Interactions 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089451/
https://www.ncbi.nlm.nih.gov/pubmed/26944820

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089451/
https://www.ncbi.nlm.nih.gov/pubmed/26944820

Ejemplares similares